Human Actrapid 40IU/ml Solution for Injection contains human insulin at a concentration of 40 international units per milliliter. It is a short-acting insulin indicated for the treatment of diabetes mellitus, including type 1 and type 2 diabetes, where glycemic control cannot be achieved by diet and exercise alone. The solution is designed to be administered subcutaneously to regulate blood glucose levels by facilitating cellular glucose uptake and inhibiting hepatic glucose production. Actrapid has an onset of action typically within 30 minutes, a peak effect between 1.5 to 3.5 hours, and a duration of action lasting up to 8 hours, making it suitable for controlling postprandial hyperglycemia. It may also be used intravenously in emergency situations such as diabetic ketoacidosis under strict medical supervision. Dosage and administration should be individualized based on patient needs, blood glucose monitoring, and lifestyle factors. Caution is advised to avoid hypoglycemia, and patients should be educated on recognizing and managing low blood sugar episodes. Actrapid should be stored according to manufacturer guidelines to maintain efficacy. It is contraindicated in patients with hypersensitivity to human insulin or any excipients in the formulation.